Suma Gopinathan
Opexa Therapeutics (United States)(US)Lexicon Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Pain Mechanisms and Treatments, Cancer Treatment and Pharmacology, Botulinum Toxin and Related Neurological Disorders, Drug Solubulity and Delivery Systems, Diabetes Treatment and Management
Most-Cited Works
- → Inhibition of Sphingosine 1-Phosphate Lyase for the Treatment of Rheumatoid Arthritis: Discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-Tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone Oxime (LX2931) and (1R,2S,3R)-1-(2-(Isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932)(2010)110 cited
- → Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma(2009)77 cited
- → Inhibition of Sphingosine-1-Phosphate Lyase for the Treatment of Autoimmune Disorders(2009)74 cited
- → Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes(2017)64 cited
- → Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma(2014)60 cited
- → Genetic Deletion of Mst1 Alters T Cell Function and Protects against Autoimmunity(2014)